SculpSure submental application now FDA-cleared for patients with BMI up to 49, the highest BMI clearance on the market MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Hologic’s (Nasdaq: HOLX) Cynosure division ...
Reduction of submental fat Patients achieved statistically significant reduction in submental fat thickness as measured from baseline vs. placebo based on MRI (p<0.05 and p<0.001, week 16 and 32, ...
SAN DIEGO, June 26, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced ...
Deoxycholic acid, an endogenously produced bile acid, has emerged as a pioneering non‐surgical treatment for reducing submental fat. By selectively inducing adipocytolysis—the breakdown of fat ...
REROVOT, Israel, March 3, 2025 /PRNewswire/ -- Raziel Therapeutics, a pharmaceutical company developing next-generation novel prescription products for the medical aesthetics market, announces phase 3 ...
Cutia Therapeutics (HK:2487) has released an update. Cutia Therapeutics has announced the completion of a Phase II clinical trial for CU-20401, a novel drug targeting submental fat reduction. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback